Full Press Release Details
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs.
“In Q2, we demonstrated the power of our platform with high impact clinical results, publication of key clinical findings, and competitive, non-dilutive, federal funding,” said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. “Since quarter-end, we further strengthened our financial position that extends our runway beyond mid-2026. With our cash position, coupled with two separate non-dilutive grants for the clinical advancement of allo-INKTs in GvHD — we can achieve substantial clinical program advancements.”
Highlights from Q2 2025
Financial Highlights
| Summary Consolidated Financial Information | |||||||||||||||
| Condensed Consolidated Balance Sheet Data | |||||||||||||||
| (in thousands) | |||||||||||||||
| (unaudited) | |||||||||||||||
| June 30, 2025 | |||||||||||||||
| Cash and cash equivalents | $ | 1,682 | |||||||||||||
| Cash raised since quarter end | 13,012 | ||||||||||||||
| Other Financial Information | |||||||||||||||
| (in thousands) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three months ended June 30, | Six months ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Cash used in operations | $ | 1,569 | $ | 2,291 | $ | 2,910 | $ | 4,833 | |||||||
| Non-cash expenses | 1,501 | 491 | 2,336 | 1,141 | |||||||||||
| Net loss | 4,237 | 2,702 | 7,004 | 6,515 | |||||||||||
| Net loss per share | 1.06 | 0.73 | 1.76 | 1.82 | |||||||||||
Conference Call and Webcast Information
MiNK will host a conference call and webcast on August 14, 2025, at 8:30 a.m. ET.
To access the live call, please dial(800) 715-9871 (U.S.) or (646) 307-1963(International) and reference conference ID 1149380.
A live webcast and replay will be available in the Events & Presentations section of MiNK’s investor website athttps://investor.minktherapeutics.com/events-and-presentations.
AboutMiNKTherapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visithttps://minktherapeutics.comor @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
ForwardLookingStatements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.